帕博利珠单抗治疗晚期复发性子宫内膜癌的成本效果分析
本研究建立模型评估帕博利珠单抗对比聚乙二醇脂质体多柔比星(PLD)或贝伐珠单抗治疗一线化疗失败的复发性子宫内膜癌的成本效果。模型纳入4400例患者,其中800例假设为MSI-H肿瘤。在MSI-H患者中,帕博利珠单抗相比PLD具有成本效果(ICER为147,249美元);在非MSI-H患者中,帕博利珠单抗相比贝伐珠单抗不具有成本效果(ICER为341,830美元)。
要点
- MSI-H复发性子宫内膜癌患者中,帕博利珠单抗相比PLD具有成本效果,ICER为147,249美元。
- 非MSI-H患者中,帕博利珠单抗相比贝伐珠单抗不具有成本效果,ICER为341,830美元。
- 非MSI-H患者中,帕博利珠单抗每周期费用需降至7253美元或以下才具有成本效果。
核心结论
- 对于一线化疗失败的MSI-H复发性子宫内膜癌患者,帕博利珠单抗相对于其他单药具有成本效果。
- 对于非MSI-H患者,帕博利珠单抗需大幅降价才具有成本效果。
研究设计与样本
- 研究建立模型,评估帕博利珠单抗对比PLD或贝伐珠单抗治疗一线化疗(卡铂和紫杉醇)失败的复发性子宫内膜癌女性的成本效果。
- 模型纳入4400例患者,其中800例假设为MSI-H肿瘤。
- 药物成本基于2016-2017年批发采购成本计算,III-IV级毒性成本根据临床经验估计。
- 效果指标为2年总生存(OS),计算增量成本效果比(ICER)以确定每2年生存者的成本,并进行单因素敏感性分析。
- 支付意愿阈值为每年OS 100,000美元。
主要发现
- 非MSI-H患者中,贝伐珠单抗相对于PLD具有成本效果,ICER为153,028美元;帕博利珠单抗相对于贝伐珠单抗不具有成本效果,ICER为341,830美元。
- MSI-H患者中,帕博利珠单抗相对于PLD具有成本效果,ICER为147,249美元;贝伐珠单抗处于扩展劣势。
- 敏感性分析显示,非MSI-H患者中,帕博利珠单抗每周期费用需降至7253美元或以下才具有成本效果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the cost-effectiveness of pembrolizumab in patients with recurrent endometrial cancer that have failed first-line chemotherapy. METHODS: We created a model to evaluate the cost-effectiveness of pembrolizumab compared to pegylated liposomal doxorubicin (PLD) or bevacizumab for the treatment of women with recurrent endometrial cancer who have failed carboplatin and paclitaxel. Microsatellite instability-high (MSI-H) and non-microsatellite instability-high (non-MSI-H) tumors were evaluated. We included 4400 patients in the model; 800 patients were assumed to have MSI-H tumors. Drug costs were calculated using 2016-2017 wholesale acquisition costs, and cost of Grade III-IV toxicities was estimated from clinical experience. Effectiveness was calculated as 2-year overall survival (OS). We calculated incremental cost-effectiveness ratios (ICERs) to determine the cost per 2-year survivor. Univariate sensitivity analyses were performed. The willingness to pay threshold was $100,000 per year of OS. RESULTS: The cost of therapy with PLD and bevacizumab were $33.2 million (M) and $167.9 M, respectively. The cost of pembrolizumab therapy was $318.3 M for non-MSI-H patients compared to $57.9 M for MSI-H patients. For non-MSI-H patients, bevacizumab was cost-effective relative to PLD with an ICER of $153,028, while pembrolizumab was not cost-effective relative to bevacizumab with an ICER of $341,830. For MSI-H patients, pembrolizumab was cost-effective compared to PLD with an ICER of $147,249, while bevacizumab was subjected to extended dominance. Sensitivity analysis revealed that for non-MSI-H patients, one cycle of pembrolizumab would need to cost $7253 or less to be cost-effective. CONCLUSIONS: For patients with MSI-H recurrent endometrial cancers who have failed first-line chemotherapy, pembrolizumab is cost-effective relative to other single agent drugs. To be cost-effective in non-MSI-H patients, the cost of pembrolizumab should decrease substantially.
引用
- Barrington DA, Dilley SE, Smith HJ, et al. Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis. Gynecol Oncol. 2019. PMID: 30808517. doi:10.1016/j.ygyno.2019.02.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。